Jazz Pharmaceuticals plc (JAZZ)
USD 105.21
(-4.39%)
USD 105.21
(-4.39%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 578.58 Million USD | 28.7% |
| 2022 | 512.26 Million USD | 200.84% |
| 2021 | 170.27 Million USD | -77.75% |
| 2020 | 765.46 Million USD | 43.78% |
| 2019 | 532.37 Million USD | -13.41% |
| 2018 | 614.83 Million USD | 16.26% |
| 2017 | 528.84 Million USD | -10.62% |
| 2016 | 591.65 Million USD | 16.42% |
| 2015 | 508.22 Million USD | 159.84% |
| 2014 | 195.58 Million USD | -42.53% |
| 2013 | 340.31 Million USD | 72.01% |
| 2012 | 197.84 Million USD | 54.77% |
| 2011 | 127.83 Million USD | 121.2% |
| 2010 | 57.78 Million USD | 262.77% |
| 2009 | 15.93 Million USD | 109.35% |
| 2008 | -170.36 Million USD | -22.76% |
| 2007 | -138.77 Million USD | -77.8% |
| 2006 | -78.05 Million USD | 0.5% |
| 2005 | -78.44 Million USD | -216.26% |
| 2004 | -24.8 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 76.2 Million USD | -62.32% |
| 2024 Q2 | 199.44 Million USD | 161.71% |
| 2023 Q2 | 157.63 Million USD | 25.05% |
| 2023 FY | 659.28 Million USD | 28.7% |
| 2023 Q4 | 202.22 Million USD | 17.3% |
| 2023 Q3 | 172.39 Million USD | 9.36% |
| 2023 Q1 | 126.05 Million USD | 12.94% |
| 2022 Q2 | 85.54 Million USD | -2.29% |
| 2022 Q1 | 87.54 Million USD | 77.3% |
| 2022 FY | 512.26 Million USD | 200.84% |
| 2022 Q4 | 111.61 Million USD | -29.54% |
| 2022 Q3 | 158.41 Million USD | 85.18% |
| 2021 Q3 | 28.36 Million USD | 140.77% |
| 2021 Q1 | 162.11 Million USD | -6.51% |
| 2021 Q2 | -69.59 Million USD | -142.93% |
| 2021 Q4 | 49.38 Million USD | 74.06% |
| 2021 FY | 170.27 Million USD | -77.75% |
| 2020 Q3 | 196.2 Million USD | -0.97% |
| 2020 FY | 765.46 Million USD | 43.78% |
| 2020 Q4 | 173.41 Million USD | -11.62% |
| 2020 Q1 | -189.67 Million USD | -409.7% |
| 2020 Q2 | 198.12 Million USD | 204.46% |
| 2019 FY | 532.37 Million USD | -13.41% |
| 2019 Q2 | 204.28 Million USD | 52.74% |
| 2019 Q3 | 133.1 Million USD | -34.84% |
| 2019 Q4 | 61.24 Million USD | -53.99% |
| 2019 Q1 | 133.74 Million USD | -27.73% |
| 2018 FY | 614.83 Million USD | 16.26% |
| 2018 Q4 | 185.05 Million USD | -1.97% |
| 2018 Q3 | 188.77 Million USD | 23.22% |
| 2018 Q2 | 153.19 Million USD | 74.47% |
| 2018 Q1 | 87.8 Million USD | -37.82% |
| 2017 Q1 | 136.14 Million USD | -17.74% |
| 2017 FY | 528.84 Million USD | -10.62% |
| 2017 Q4 | 141.2 Million USD | 63.33% |
| 2017 Q3 | 86.45 Million USD | -47.62% |
| 2017 Q2 | 165.04 Million USD | 21.23% |
| 2016 FY | 591.65 Million USD | 16.42% |
| 2016 Q1 | 121.16 Million USD | 13.63% |
| 2016 Q4 | 165.5 Million USD | 21.47% |
| 2016 Q3 | 136.25 Million USD | -19.25% |
| 2016 Q2 | 168.73 Million USD | 39.26% |
| 2015 Q3 | 131.53 Million USD | -14.2% |
| 2015 FY | 508.22 Million USD | 159.84% |
| 2015 Q1 | 116.75 Million USD | -10.13% |
| 2015 Q2 | 153.3 Million USD | 31.3% |
| 2015 Q4 | 106.62 Million USD | -18.93% |
| 2014 Q2 | 74.29 Million USD | 211.45% |
| 2014 FY | 195.58 Million USD | -42.53% |
| 2014 Q1 | -66.65 Million USD | -170.54% |
| 2014 Q4 | 129.91 Million USD | 123.86% |
| 2014 Q3 | 58.03 Million USD | -21.88% |
| 2013 Q4 | 94.49 Million USD | -6.03% |
| 2013 FY | 340.31 Million USD | 72.01% |
| 2013 Q2 | 77.06 Million USD | 13.02% |
| 2013 Q1 | 68.18 Million USD | 1.2% |
| 2013 Q3 | 100.56 Million USD | 30.49% |
| 2012 Q2 | 35.45 Million USD | 6.85% |
| 2012 FY | 197.84 Million USD | 54.77% |
| 2012 Q1 | 33.18 Million USD | -11.89% |
| 2012 Q4 | 67.37 Million USD | 21.84% |
| 2012 Q3 | 55.3 Million USD | 55.95% |
| 2011 Q1 | 22.6 Million USD | -11.48% |
| 2011 Q2 | 33.85 Million USD | 49.79% |
| 2011 Q3 | 33.7 Million USD | -0.46% |
| 2011 Q4 | 37.66 Million USD | 11.75% |
| 2011 FY | 127.83 Million USD | 121.2% |
| 2010 FY | 57.78 Million USD | 262.77% |
| 2010 Q2 | 10.58 Million USD | 46.38% |
| 2010 Q1 | 7.22 Million USD | -36.64% |
| 2010 Q4 | 25.53 Million USD | 76.8% |
| 2010 Q3 | 14.44 Million USD | 36.49% |
| 2009 Q3 | 3.7 Million USD | -53.83% |
| 2009 Q4 | 11.41 Million USD | 207.63% |
| 2009 FY | 15.93 Million USD | 109.35% |
| 2009 Q2 | 8.03 Million USD | 211.23% |
| 2009 Q1 | -7.22 Million USD | 86.03% |
| 2008 Q3 | -27.74 Million USD | 41.09% |
| 2008 Q4 | -51.71 Million USD | -86.42% |
| 2008 Q1 | -43.8 Million USD | 25.43% |
| 2008 Q2 | -47.09 Million USD | -7.5% |
| 2008 FY | -170.36 Million USD | -22.76% |
| 2007 Q1 | -19.48 Million USD | 82.48% |
| 2007 Q4 | -58.74 Million USD | -230.06% |
| 2007 Q2 | -42.75 Million USD | -119.44% |
| 2007 Q3 | -17.79 Million USD | 58.37% |
| 2007 FY | -138.77 Million USD | -77.8% |
| 2006 Q4 | -111.23 Million USD | -1052.93% |
| 2006 FY | -78.05 Million USD | 0.5% |
| 2006 Q1 | 9.83 Million USD | 113.43% |
| 2006 Q2 | 11.67 Million USD | 18.66% |
| 2006 Q3 | 11.67 Million USD | 0.0% |
| 2005 Q4 | -73.22 Million USD | -1465.9% |
| 2005 Q2 | 5.36 Million USD | 0.0% |
| 2005 FY | -78.44 Million USD | -216.26% |
| 2005 Q1 | 5.36 Million USD | 0.0% |
| 2005 Q3 | 5.36 Million USD | 0.0% |
| 2004 FY | -24.8 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 343.914% |
| Alkermes plc | 414.12 Million USD | -39.712% |
| Agenus Inc. | -159.54 Million USD | 462.635% |
| Aptorum Group Limited | -10.52 Million USD | 5598.07% |
| Ardelyx, Inc. | -63.27 Million USD | 1014.375% |
| Dyadic International, Inc. | -8.22 Million USD | 7130.357% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 48638.591% |
| Lantern Pharma Inc. | -17.87 Million USD | 3336.346% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 2979.97% |
| Novavax, Inc. | -566.51 Million USD | 202.13% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 892.803% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 803.903% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 3079.527% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 5577.421% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 1189.063% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 252.059% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 2480.34% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 1627.846% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 548.553% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 789.492% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 3398.82% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 1414.656% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 2428.852% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 516.152% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 305.043% |
| AlloVir, Inc. | -181.33 Million USD | 419.074% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 382.231% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 2077.51% |
| Bicycle Therapeutics plc | -189.94 Million USD | 404.602% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 436.811% |
| ChromaDex Corporation | -5.59 Million USD | 10433.631% |
| Chimerix, Inc. | -93.06 Million USD | 721.695% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 1383.528% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 598.522% |
| CRISPR Therapeutics AG | -222.53 Million USD | 359.992% |
| Precision BioSciences, Inc. | -43.73 Million USD | 1422.892% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 403.699% |
| Fortress Biotech, Inc. | -142.34 Million USD | 506.472% |
| Fortress Biotech, Inc. | -142.34 Million USD | 506.472% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 692.237% |
| ImmuCell Corporation | -5.74 Million USD | 10165.625% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 530.398% |
| Immix Biopharma, Inc. | -16.14 Million USD | 3684.511% |
| Incyte Corporation | 620.52 Million USD | 6.76% |
| Innoviva, Inc. | 176.7 Million USD | -227.42% |
| IO Biotech, Inc. | -91.44 Million USD | 732.722% |
| Jaguar Health, Inc. | -34.29 Million USD | 1787.265% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 440.459% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -4744.917% |
| ContextLogic Inc. | -328 Million USD | 276.396% |
| MiMedx Group, Inc. | 37.11 Million USD | -1458.843% |
| MEI Pharma, Inc. | 14.54 Million USD | -3878.682% |
| NextCure, Inc. | -67.63 Million USD | 955.419% |
| Onconetix, Inc. | -36.03 Million USD | 1705.624% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 1487.016% |
| Opthea Limited | -191.84 Million USD | 401.591% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 21125.32% |
| Vaxcyte, Inc. | -468.04 Million USD | 223.617% |
| PDS Biotechnology Corporation | -43.04 Million USD | 1444.121% |
| Precigen, Inc. | -88.92 Million USD | 750.653% |
| Pharming Group N.V. | -4.87 Million USD | 11957.256% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 445.809% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 2044.415% |
| PureTech Health plc | -146.19 Million USD | 495.748% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 2923.581% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 345.579% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 2480.34% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 311.157% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 2074.339% |
| Acelyrin, Inc. | -422.06 Million USD | 237.083% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 4486976.248% |
| Summit Therapeutics Inc. | -89.73 Million USD | 744.758% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 1661.03% |
| Senti Biosciences, Inc. | -92.72 Million USD | 723.961% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 604.108% |
| Elevation Oncology, Inc. | -45.44 Million USD | 1373.143% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 1788.447% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 14777.142% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 18397.913% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 1852.158% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 6906.023% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 950.903% |
| Seer, Inc. | -103.46 Million USD | 659.214% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 979.849% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 904.332% |
| ESSA Pharma Inc. | -32.13 Million USD | 1900.517% |
| GlycoMimetics, Inc. | -39.27 Million USD | 1573.14% |
| GT Biopharma, Inc. | -13.57 Million USD | 4361.786% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 363.925% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 1350.822% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -566.475% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 1119.363% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 1223.325% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 5922.104% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 214.726% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 8487.649% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 1241.341% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 322.823% |
| Aptose Biosciences Inc. | -52.35 Million USD | 1205.088% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 4112.129% |
| Soligenix, Inc. | -7.69 Million USD | 7616.037% |
| Century Therapeutics, Inc. | -146.54 Million USD | 494.811% |
| Kura Oncology, Inc. | -165.8 Million USD | 448.954% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 719.08% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 7054.922% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 23414.431% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 9023.196% |
| Autolus Therapeutics plc | -195.02 Million USD | 396.665% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 783.44% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 885.452% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 2837.544% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 354.842% |
| GRI Bio, Inc. | -11.38 Million USD | 5181.057% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 12912.589% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 541.014% |
| IGM Biosciences, Inc. | -263.46 Million USD | 319.607% |
| INmune Bio, Inc. | -29.74 Million USD | 2045.395% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 623.057% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 1619.567% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 3720.796% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 3768.673% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 1046.97% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 638.104% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 309.626% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 384.736% |
| Verastem, Inc. | -92.08 Million USD | 728.318% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 1327.495% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 414.198% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 588.748% |
| Histogen Inc. | -10.64 Million USD | 5536.249% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 3839.539% |
| Surrozen, Inc. | -45.78 Million USD | 1363.827% |
| Organovo Holdings, Inc. | -15.08 Million USD | 3935.211% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 11466.467% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 1075.988% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 1227.968% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 2388.687% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 7680.138% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 437.792% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 1294.23% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 839.825% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 3901.252% |
| Apollomics, Inc. | -54.83 Million USD | 1155.148% |
| Amarin Corporation plc | -67.58 Million USD | 956.04% |
| Mesoblast Limited | -58.79 Million USD | 1084.08% |
| Turnstone Biologics Corp. | -59.03 Million USD | 1080.112% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 449.532% |
| Synaptogenix, Inc. | -8.31 Million USD | 7059.227% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 4066.68% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 731.011% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 12175.219% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 6651.519% |
| Exelixis, Inc. | 170.88 Million USD | -238.579% |
| Better Therapeutics, Inc. | -38.26 Million USD | 1612.153% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 473.126% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 211.885% |
| NLS Pharmaceutics AG | -11.8 Million USD | 5000.287% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 7294.563% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 2029.05% |
| Gritstone bio, Inc. | -154.63 Million USD | 474.161% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 940.214% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 3478.954% |
| Avid Bioservices, Inc. | -18.67 Million USD | 3197.655% |
| Insmed Incorporated | -709.62 Million USD | 181.533% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 3787.622% |
| MediWound Ltd. | -15.29 Million USD | 3884.042% |
| OmniAb, Inc. | -69.41 Million USD | 933.461% |
| Alector, Inc. | -151.74 Million USD | 481.297% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 635.807% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 1209.496% |
| Zai Lab Limited | -366.57 Million USD | 257.835% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 282.646% |
| Aura Biosciences, Inc. | -84.99 Million USD | 780.754% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 335.675% |
| Immunic, Inc. | -99.22 Million USD | 683.111% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 504.155% |
| Veracyte, Inc. | -85.79 Million USD | 774.375% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 305.305% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 4171.64% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 8499.89% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 3178.762% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 2373.131% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | -1391.109% |
| TG Therapeutics, Inc. | 20.63 Million USD | -2704.149% |
| Galecto, Inc. | -39.9 Million USD | 1549.893% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 1475.149% |
| Fortrea Holdings Inc. | 63.1 Million USD | -816.926% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 511.962% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 2103.532% |
| XBiotech Inc. | -37.51 Million USD | 1642.469% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 940.214% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 962.008% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 636.189% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 2353.739% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 1185.679% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 201.646% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 837.12% |
| Vaxxinity, Inc. | -58.28 Million USD | 1092.674% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 657.888% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 2699.993% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 769.529% |
| NexImmune, Inc. | -29.19 Million USD | 2081.949% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 10394.776% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 4067.938% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 85.704% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 2372.595% |
| Scopus BioPharma Inc. | -11.71 Million USD | 5038.848% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 555.353% |
| Ainos, Inc. | -13.2 Million USD | 4481.059% |
| Pluri Inc. | -22.15 Million USD | 2711.156% |
| Prothena Corporation plc | -191.03 Million USD | 402.864% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 519.145% |
| Celularity Inc. | -192.28 Million USD | 400.894% |
| Rallybio Corporation | -78.93 Million USD | 833.011% |
| Cue Biopharma, Inc. | -52.14 Million USD | 1209.475% |
| MeiraGTx Holdings plc | -137.06 Million USD | 522.133% |
| Omeros Corporation | -164.53 Million USD | 451.656% |
| Humacyte, Inc. | -100.04 Million USD | 678.308% |
| Immunocore Holdings plc | -59.64 Million USD | 1069.974% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 3217.517% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 2463.191% |
| Blueprint Medicines Corporation | -486.27 Million USD | 218.982% |
| CalciMedica, Inc. | -21.87 Million USD | 2744.937% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 874.953% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 540.035% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 437.768% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 276.99% |
| Pulmatrix, Inc. | -14.74 Million USD | 4025.237% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 1718.632% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 751.07% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 212.282% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 956.508% |
| Cytokinetics, Incorporated | -496.2 Million USD | 216.601% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 1780.99% |
| Nutriband Inc. | -4.87 Million USD | 11975.796% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 1426.623% |
| Vor Biopharma Inc. | -126.03 Million USD | 559.059% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 86.361% |
| Evogene Ltd. | -26.39 Million USD | 2292.338% |
| ProKidney Corp. | -151.52 Million USD | 481.846% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 996.537% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 7621.604% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 195.26% |
| CorMedix Inc. | -48.95 Million USD | 1281.794% |
| BioLineRx Ltd. | -49.69 Million USD | 1264.285% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 606.757% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 1619.7% |
| Atai Life Sciences N.V. | -125.47 Million USD | 561.126% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 808.703% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 810.708% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 332.373% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 1982.173% |
| MediciNova, Inc. | -9.9 Million USD | 5944.086% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 557.835% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 8088.723% |
| GeoVax Labs, Inc. | -26.74 Million USD | 2263.487% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 349.576% |
| Biomea Fusion, Inc. | -126.13 Million USD | 558.699% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 265.591% |
| Mereo BioPharma Group plc | -28.41 Million USD | 2136.106% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 402.78% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 351.607% |
| Absci Corporation | -115.51 Million USD | 600.87% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 2197.292% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 612.621% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 338.923% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 2396.317% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 378.171% |
| Allakos Inc. | -196.05 Million USD | 395.11% |
| Imunon, Inc. | -21.03 Million USD | 2851.156% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 622.826% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -439.308% |
| BioAtla, Inc. | -129.68 Million USD | 546.136% |
| NLS Pharmaceutics AG | -11.8 Million USD | 5000.287% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 3751.96% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 276.538% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 1485.555% |
| XOMA Corporation | -41.84 Million USD | 1482.575% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 649.788% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 576.217% |
| aTyr Pharma, Inc. | -54.91 Million USD | 1153.515% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 761.786% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 434.691% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 327.385% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 2795.332% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 7144.895% |
| Akari Therapeutics, Plc | -16.8 Million USD | 3542.699% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 6542880.02% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -71.394% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 8954.883% |
| UroGen Pharma Ltd. | -65.53 Million USD | 982.843% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 748.066% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 8066.117% |
| Orgenesis Inc. | -53.63 Million USD | 1178.716% |
| Entera Bio Ltd. | -8.89 Million USD | 6607.479% |
| GH Research PLC | -41.22 Million USD | 1503.571% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 2350.583% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 796.639% |
| Xencor, Inc. | -138.63 Million USD | 517.328% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 11324.574% |
| Replimune Group, Inc. | -234.77 Million USD | 346.442% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 2792.182% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 4246.932% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 8954.883% |
| Portage Biotech Inc. | -18.25 Million USD | 3269.78% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 8088.723% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 651.233% |
| OncoCyte Corporation | -25.13 Million USD | 2401.798% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 5217.977% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 5149.986% |
| Purple Biotech Ltd. | 22.27 Million USD | -2497.908% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 7802.077% |
| scPharmaceuticals Inc. | -55.39 Million USD | 1144.444% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 3161.644% |
| HilleVax, Inc. | -133.34 Million USD | 533.897% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 4901.892% |
| Tharimmune, Inc. | -9.45 Million USD | 6219.16% |
| Genprex, Inc. | -31.07 Million USD | 1961.848% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 407.438% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 1943.962% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 75731.373% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 10722.152% |
| OKYO Pharma Limited | -15.74 Thousand USD | 3673686.785% |
| Savara Inc. | -60 Million USD | 1064.188% |
| Curis, Inc. | -48.33 Million USD | 1297.095% |
| Daré Bioscience, Inc. | -30.83 Million USD | 1976.077% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 11189.687% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 8050.804% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 2223.229% |
| BeiGene, Ltd. | -1.2 Billion USD | 147.906% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 3001.707% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 218.76% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 717.798% |
| Erasca, Inc. | -141.52 Million USD | 508.818% |
| bluebird bio, Inc. | -244.26 Million USD | 336.869% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 12880.723% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -197.561% |
| DBV Technologies S.A. | -76.43 Million USD | 856.987% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 12880.723% |
| Moderna, Inc. | -4.23 Billion USD | 113.649% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 1457.882% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 9197.17% |
| Molecular Templates, Inc. | -10.46 Million USD | 5628.187% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 960.508% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 253.574% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 503.723% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 1212.804% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 474.384% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 377.99% |
| MacroGenics, Inc. | -168.24 Million USD | 443.893% |
| RenovoRx, Inc. | -11.39 Million USD | 5177.045% |
| Adicet Bio, Inc. | -152.03 Million USD | 480.55% |
| Prime Medicine, Inc. | -191.29 Million USD | 402.459% |
| Aditxt, Inc. | -26.06 Million USD | 2319.978% |
| Adagene Inc. | -23.71 Million USD | 2539.221% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 8014.805% |
| Quantum-Si incorporated | -111.17 Million USD | 620.441% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 1928.172% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 4068.92% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | -374.191% |
| SciSparc Ltd. | -5.77 Million USD | 10122.172% |
| Vericel Corporation | -6.46 Million USD | 9050.804% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 6783.637% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 2602.555% |
| Generation Bio Co. | -138.56 Million USD | 517.557% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 796.832% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 769.188% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 339.974% |
| Invivyd, Inc. | -207.78 Million USD | 378.454% |
| Relay Therapeutics, Inc. | -373 Million USD | 255.115% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 6269.214% |
| Spero Therapeutics, Inc. | 21.48 Million USD | -2593.45% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 5724.38% |
| 2seventy bio, Inc. | -216.7 Million USD | 366.992% |
| ADMA Biologics, Inc. | 21.63 Million USD | -2574.649% |
| Clene Inc. | -40.54 Million USD | 1527.183% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 2502.955% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 1155.88% |
| GeoVax Labs, Inc. | -26.74 Million USD | 2263.487% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 265.28% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 1675.138% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -3498.806% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 657.926% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 1801.606% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 439.786% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 184.55% |
| Evaxion Biotech A/S | -22.19 Million USD | 2706.568% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 802.314% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 359.309% |
| Trevena, Inc. | -35.28 Million USD | 1739.594% |
| Surrozen, Inc. | -45.78 Million USD | 1363.827% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 823.723% |
| Cingulate Inc. | -22.75 Million USD | 2642.182% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -7622.637% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 1395.319% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 7126.769% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 664.149% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 888.482% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 1032.081% |
| Clearmind Medicine Inc. | -8.74 Million USD | 6718.886% |
| Kronos Bio, Inc. | -121.83 Million USD | 574.908% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 859.331% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 19826.661% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 673.834% |
| Statera Biopharma, Inc. | -98.34 Million USD | 688.324% |
| ImmunityBio, Inc. | -362.25 Million USD | 259.718% |
| Korro Bio, Inc. | -84.53 Million USD | 784.435% |
| Kineta, Inc. | -15.72 Million USD | 3779.832% |
| BioVie Inc. | -32.17 Million USD | 1897.972% |
| Codexis, Inc. | -68.06 Million USD | 949.99% |
| Celularity Inc. | -192.28 Million USD | 400.894% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 359.91% |
| Celcuity Inc. | -66.23 Million USD | 973.588% |
| Virax Biolabs Group Limited | -6.49 Million USD | 9006.063% |
| Cibus, Inc. | -318.88 Million USD | 281.44% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 1445.535% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 1809.55% |
| IN8bio, Inc. | -30.33 Million USD | 2007.176% |
| Kodiak Sciences Inc. | -277.32 Million USD | 308.632% |
| Annexon, Inc. | -143.72 Million USD | 502.566% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 567.385% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 994.997% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 2567.924% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 263.565% |
| Eyenovia, Inc. | -25.4 Million USD | 2377.296% |
| Puma Biotechnology, Inc. | 32.64 Million USD | -1672.61% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 10502.373% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 831.149% |
| Arcellx, Inc. | -89.88 Million USD | 743.725% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 1374.069% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 521.684% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 1959.848% |
| Moolec Science SA | -6.65 Million USD | 8795.476% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 1046.351% |
| Geron Corporation | -193.94 Million USD | 398.323% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 1437.664% |
| Royalty Pharma plc | 1.49 Billion USD | 61.225% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 452.445% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 6302.705% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 2742.562% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 438.436% |
| Humacyte, Inc. | -100.04 Million USD | 678.308% |
| Structure Therapeutics Inc. | -102.77 Million USD | 662.958% |
| 89bio, Inc. | -151.2 Million USD | 482.649% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 822.034% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 4079.23% |
| Genelux Corporation | -24.16 Million USD | 2494.289% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 1805.568% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 436.873% |
| Notable Labs, Ltd. | -14.65 Million USD | 4047.465% |
| Liquidia Corporation | -73.38 Million USD | 888.428% |
| Mustang Bio, Inc. | -50.72 Million USD | 1240.599% |
| Immunovant, Inc. | -282.7 Million USD | 304.656% |
| Quantum-Si incorporated | -111.17 Million USD | 620.441% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 840.791% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 2820.553% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 667.169% |
| Acasti Pharma Inc. | -11.31 Million USD | 5214.745% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 2624.224% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 3720.796% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 370.296% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 15869.11% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 3742.075% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 2084.361% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 1498.077% |
| PepGen Inc. | -84.76 Million USD | 782.561% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 2052.617% |
| United Therapeutics Corporation | 1.18 Billion USD | 51.171% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 2626.881% |
| Solid Biosciences Inc. | -104.31 Million USD | 654.647% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 1863.527% |
| Immuneering Corporation | -58.41 Million USD | 1090.501% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 11466.467% |
| Silo Pharma, Inc. | -3.85 Million USD | 15106.256% |
| Belite Bio, Inc | -31.66 Million USD | 1927.018% |
| XOMA Corporation | -41.84 Million USD | 1482.575% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 956.902% |
| Bionomics Limited | -17.89 Billion USD | 103.234% |
| Apogee Therapeutics, Inc. | -93 Million USD | 722.109% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -1521.581% |
| uniQure N.V. | -282.87 Million USD | 304.538% |
| Cassava Sciences, Inc. | -105.95 Million USD | 646.052% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 8014.805% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 546.766% |
| Forte Biosciences, Inc. | -32.48 Million USD | 1881.013% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 7063.498% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 2068.294% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 10502.373% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 4171.64% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 6608.944% |
| Altimmune, Inc. | -95.92 Million USD | 703.134% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 887.248% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -1521.581% |
| Compugen Ltd. | -12.99 Million USD | 4553.356% |
| Peak Bio, Inc. | -1356.23 USD | 42661005.599% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 1266.398% |
| Benitec Biopharma Inc. | -22.49 Million USD | 2672.61% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 338.784% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 2045.068% |
| Zura Bio Limited | -62.63 Million USD | 1023.688% |
| PolyPid Ltd. | -22.86 Million USD | 2630.196% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 3654.805% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 2045.068% |
| Instil Bio, Inc. | -159.16 Million USD | 463.5% |
| argenx SE | -425.04 Million USD | 236.121% |
| Immunome, Inc. | -109.53 Million USD | 628.239% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 1248.82% |
| Verona Pharma plc | -67.83 Million USD | 952.974% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 2320.184% |
| Shattuck Labs, Inc. | -91.95 Million USD | 729.185% |
| CervoMed Inc. | -7.81 Million USD | 7505.45% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 891.383% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 4443.368% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 1301.021% |
| Moolec Science SA | -6.65 Million USD | 8795.476% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 3617.537% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 527.859% |
| AnaptysBio, Inc. | -164.41 Million USD | 451.911% |
| Design Therapeutics, Inc. | -78.19 Million USD | 839.967% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 764.721% |
| NeurAxis, Inc. | -6.66 Million USD | 8781.528% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 1528.628% |
| Lumos Pharma, Inc. | -36.61 Million USD | 1680.215% |
| Achilles Therapeutics plc | -75.25 Million USD | 868.826% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 2320.184% |
| 180 Life Sciences Corp. | -13.47 Million USD | 4392.933% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -11120.813% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 19826.661% |
| Nutriband Inc. | -4.87 Million USD | 11975.796% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 622.278% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 1143.445% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 1238.13% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 975.323% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 1169.008% |
| Palisade Bio, Inc. | -13.07 Million USD | 4526.779% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 1374.153% |
| Beam Therapeutics Inc. | -176.48 Million USD | 427.835% |
| Neurogene Inc. | -55.58 Million USD | 1140.93% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 630.058% |
| AEON Biopharma, Inc. | -48.42 Million USD | 1294.697% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 698.263% |
| Sesen Bio, Inc. | -25.9 Million USD | 2333.124% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 792.67% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 4696.685% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 225.626% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 898.713% |
| Athira Pharma, Inc. | -125.46 Million USD | 561.145% |
| Vaccinex, Inc. | -22.88 Million USD | 2628.206% |
| HCW Biologics Inc. | -25.71 Million USD | 2349.782% |
| XOMA Corporation | -41.84 Million USD | 1482.575% |
| Nektar Therapeutics | -137.42 Million USD | 521.015% |
| Arvinas, Inc. | -401.5 Million USD | 244.105% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 6542880.02% |
| Merus N.V. | -156.54 Million USD | 469.589% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 677.074% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 1771.231% |
| Rezolute, Inc. | -70.42 Million USD | 921.578% |
| Clene Inc. | -40.54 Million USD | 1527.183% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 3632.564% |
| BeyondSpring Inc. | -23.11 Million USD | 2603.158% |
| Synlogic, Inc. | -55.16 Million USD | 1148.893% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 3327.062% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 5445.344% |
| Peak Bio, Inc. | -1356.23 USD | 42661005.599% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 1528.487% |
| Krystal Biotech, Inc. | -109.72 Million USD | 627.29% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 546.642% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 268.676% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 12291.018% |
| MannKind Corporation | 8.67 Million USD | -6567.204% |
| Ikena Oncology, Inc. | -75.41 Million USD | 867.175% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 6097.512% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 960.598% |
| Gossamer Bio, Inc. | -183.75 Million USD | 414.858% |
| CohBar, Inc. | -12.38 Million USD | 4770.376% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 1240.643% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 2197.292% |
| Legend Biotech Corporation | -439.48 Million USD | 231.65% |
| Mural Oncology plc | -194.63 Million USD | 397.26% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 961.713% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 3683.588% |
| Disc Medicine, Inc. | -91.12 Million USD | 734.93% |
| Champions Oncology, Inc. | -7.35 Million USD | 7965.416% |
| REGENXBIO Inc. | -268.12 Million USD | 315.785% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 5498.114% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 1137.7% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 1585.037% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 605.942% |
| Vaxart, Inc. | -83.34 Million USD | 794.182% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 6890.839% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 1452.009% |
| Cellectis S.A. | -106.62 Million USD | 642.626% |
| Longeveron Inc. | -21.02 Million USD | 2851.343% |
| Repare Therapeutics Inc. | -116.22 Million USD | 597.815% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 316.03% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 864.862% |
| Revolution Medicines, Inc. | -487.18 Million USD | 218.76% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 8797.835% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 1416.331% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 875.68% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 930.875% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 5354.564% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 86.568% |
| Denali Therapeutics Inc. | -196.69 Million USD | 394.145% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 6783.637% |
| Veru Inc. | -93.78 Million USD | 716.94% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 2580.089% |
| Cingulate Inc. | -22.75 Million USD | 2642.182% |
| Passage Bio, Inc. | -108.38 Million USD | 633.8% |
| Context Therapeutics Inc. | -25.07 Million USD | 2407.617% |
| Exicure, Inc. | -14.99 Million USD | 3958.229% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 380.777% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 1525.144% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 6054.345% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 413.837% |
| Nuvalent, Inc. | -149.49 Million USD | 487.031% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 7141.677% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 752.061% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 2885.116% |
| OmniAb, Inc. | -69.41 Million USD | 933.461% |
| Anew Medical, Inc. | -1.3 Million USD | 44577.415% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 4630.42% |
| Lipocine Inc. | -17.93 Million USD | 3326.71% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 944.482% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 859.77% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 1619.567% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 1563.759% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 2684.793% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 199.781% |
| Ocugen, Inc. | -65.53 Million USD | 982.91% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 716.389% |
| Q32 Bio Inc. | -92.1 Million USD | 728.195% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 2798.727% |
| Alumis Inc. Common Stock | -158.17 Million USD | 465.787% |
| Equillium, Inc. | -14.52 Million USD | 4084.162% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 1027.122% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 7420.694% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 3166.932% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 1332.306% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 633.421% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 4933.578% |
| Dominari Holdings Inc. | -21.79 Million USD | 2754.524% |
| Edesa Biotech, Inc. | -9.22 Million USD | 6373.395% |
| vTv Therapeutics Inc. | -25.5 Million USD | 2368.763% |
| Bio-Techne Corporation | 206.68 Million USD | -179.932% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 247.79% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | -201.297% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 537.4% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 1607.072% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 482.909% |
| Nkarta, Inc. | -131.65 Million USD | 539.483% |
| BioCardia, Inc. | -11.64 Million USD | 5068.911% |
| Iterum Therapeutics plc | -47.46 Million USD | 1318.884% |